OMAR COLON: Open Payments
NPI 1093061293 · OSWEGO, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$24,228 in 102 payments from 11 companies in 2025. Trend: 2023 $29,731 · 2024 $13,504 · 2025 $24,228
Consulting: $15,275Speaker / faculty: $4,600Travel & lodging: $2,320Food & beverage: $2,033
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 47 | $16,495 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $7,008 |
| Alkermes, Inc. | 8 | $183 |
| Teva Pharmaceuticals USA, Inc. | 10 | $173 |
| Otsuka America Pharmaceutical, Inc. | 7 | $131 |
| Neurocrine BioSciences, Inc. | 4 | $90 |
| ABBVIE INC. | 4 | $68 |
| Vanda Pharmaceuticals Inc. | 1 | $29 |
| Lundbeck LLC | 1 | $24 |
| Luye Pharma (USA) Ltd. | 1 | $18 |
Products named: CAPLYTA, COBENFY, ARISTADA, UZEDY, INGREZZA, VRAYLAR, REXULTI, ABILIFY MAINTENA.
Industry payments across NY — which companies pay providers there.
